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Background/aim: High flow nasal cannula (HFNC) was mostly used in intensive care units (ICUs) with few studies in other departments.
We hypothesized that HFNC applied at wards is beneficial for acute respiratory failure in hematological malignancy patients.
Materials and methods: The study is a single center, randomized controlled study. Inclusion criteria were hypoxemic respiratory failure
and hematological malignancy. Patients were randomized to either venturi mask/nasal cannula oxygen treatment or HFNC.
Results: One hundred patients were included in the study. Median age was 58.5 (18–86) years and APACHE II score was 17 (5–29).
HFNC group was 51 patients and the oxygen treatment group 49 patients. P/F ratios were similar between the groups throughout the
study period. Endotracheal intubation was required in 10 (20.0%) patients in oxygen group and 17 (33.0%) patients in HFNC group
(p = 0.14). A total of 17 (35.0%) patients in oxygen group and 17 (33.0%) patients in HFNC group received noninvasive mechanical
ventilation (p = 0.97). Median VAS comfort scores at the 2nd and 24th hours were not different between groups. The 28-day mortality
rate was 36.7% (18 deaths) in the standard group and 45.0% (23 deaths) in the HFNC group (p = 0.39).
Conclusion: HFNC applied in wards is not superior to standard oxygen treatment for acute respiratory failure in hematological
malignancy patients.
Key words: Acute respiratory failure, high flow nasal oxygen, hematological malignancy

1. Introduction
New and effective treatment techniques for hematological
patients introduced during the last decade improved
survival and disease-free periods [1,2]. Increasing number
of hematological malignancy patients require intensive
care unit (ICU) admissions with improved survival and
immunosuppression related problems [3].
Acute respiratory failure is the leading cause for ICU
admission for immunocompromised and especially for
hematological patients [4]. Endotracheal intubation and
invasive mechanical ventilation requirement are associated
with very high mortality rates up to 70% in these subgroup
of patients [5]. This prompted to seek alternative techniques
of respiratory support to determine if it is possible to avoid
from invasive mechanical ventilation [5–7]. Respiratory
support in early stages of hypoxemic acute respiratory
failure in immunocompromised patients was debated
before [5,8,9]. In the largest randomized controlled study
reported in 2015, early noninvasive ventilation compared

with oxygen therapy alone did not reduce mortality, ICUacquired infections, duration of mechanical ventilation,
or lengths of ICU or hospital stays in this subset of the
patients [10]. However, authors declared that the study
was underpowered.
Oxygen treatment either with nasal cannula or face
mask is the first step treatment in hypoxic respiratory
failure to improve oxygenation. Flow rates are limited
with these devices because these devices are unable to
achieve appropriate level of heat and humidity with high
flow rates. The fraction of oxygen given to the patient is
also highly variable with these devices. High flow oxygen
devices are available during the last decade that can deliver
oxygen up to 60 L/min with active heated humidification
[11]. The fraction of oxygen is also can be adjusted with
an oxygen blender incorporated into the system. High
flow oxygen provided with a nasal cannula flushes out
carbon dioxide from anatomical dead space and decreases
respiratory rate [12]. High flow nasal oxygen also provides
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greater comfort, tolerability, better respiratory pattern and
oxygenation compared to other low flow system devices.
High flow nasal oxygen was proved to be beneficial in
various forms of acute respiratory failure patients [13–17]
As application of high flow nasal oxygen in adult ICUs
is relatively recent, the evidence supporting its use remains
limited and is composed of predominantly observational
studies [18]. There are also a limited number of studies in
immunocompromised patients [19]. A recent randomized
controlled study in immunocompromised patients
showed that high flow oxygen therapy did not significantly
decrease 28-day mortality and the need for endotracheal
intubation when compared with standard oxygen therapy
[20]. Most studies on high flow nasal oxygen in patients
with hypoxemia have been conducted in an intensive care
unit or high-dependency unit. There are discussions if
high flow nasal oxygen for acute respiratory failure should
be used only in intensive care units or not [21].
We hypothesized that HFNC performed in hematology
wards can decrease need for invasive, noninvasive
mechanical ventilation and need for ICU admission in
acute respiratory failure of hematological malignancies.
2. Patients and methods
The study is a single center, prospective, open label
randomized controlled study comparing standard oxygen
treatment vs. high flow nasal oxygen (HFNC) in early phase
of acute hypoxemic respiratory failure of hematological
malignancy patients. Patient recruitment was performed
between November 2016 and September 2018. The study
was conducted in a university hospital in Kayseri, Turkey.
The study protocol was approved by Erciyes University
ethics committee (2016/596). Written informed consent
was obtained from all patients.
2.1. Patients
The patients were recruited in hematology and bone
marrow transplantation clinics of Erciyes University
Hospital. Eligible patients were hematological malignancy
patients regardless of time from diagnosis or bone marrow
transplant patients with signs of respiratory distress or
labored breathing. Inclusion criteria were (1) Patients
above 18 years of age, (2) PaO2/FiO2 < 300 mmHg or
oxygen saturation by pulse oximetry (SpO2) < 92% on
room air, (3) PaCO2 ≤ 45 mmHg, (4) respiratory rate > 22
breaths/min or labored breathing with respiratory distress.
Exclusion criteria were (1) Patients refused to enter
into the study, (2) Pregnant or breast-feeding patients,
(3) Need for noninvasive (NIMV) or invasive mechanical
ventilation (IMV) at the time of randomization, (4) Need
for intensive care unit (ICU) admission at the time of
randomization, (5) PaCO2 > 45 mmHg, (6) Hemodynamic
instability (mean arterial pressure less than 65 mmHg
and/or need for vasopressors), (7) Cardiogenic pulmonary
edema, (8) Patients unable to cooperate.

2.2. Randomization
Clinicians participating in the study were randomly
given sealed and opaque envelopes containing treatment
allocation as either high-flow nasal oxygen therapy or
standard oxygen therapy. The envelope was opened, and
the allotted treatment given after the patient gave its
written informed consent.
2.3. Treatments
Treatments other than oxygen and HFNC treatment were
made by clinical team caring for these patients according
to their standard practice for both groups. Oxygen or
HFNC treatments were initiated within 30 min after
randomization. Respiratory treatments such as respiratory
therapy and bronchodilators were also managed by the
physicians caring for the patients.
2.4. High-flow oxygen treatment
Initial flow rate was started as 30 L/min with FiO2 of 100%
and flow rate increased up to 50 L/min as for patient’s
tolerability. FiO2 is adjusted to keep SpO2 ≥ 94%. Minimal
flow rate used is 30 L/min during the study period. HFNC
is used as much as possible during the study period
including mealtimes, procedures and transfers. HFNC was
weaned per patient’s improvement in clinical signs. We
have started give breaks if PaO2/FiO2 ≥ 350 and ability to
keep SpO2 ≥ 94% with nasal cannula or face mask oxygen
without any signs of respiratory distress.
2.5. Oxygen treatment
Oxygen was provided with nasal prongs or facial oxygen
masks without reservoir bag. Initial oxygen flow was 6 L/
min and adjusted to keep SpO2 ≥ 94 %. HFNC is never
used in standard oxygen treatment patients. NIMV or
IMV with endotracheal intubation is used in case of failure
based the criteria described below.
2.6. Treatment failure
Treatment failure was diagnosed in case of (1) metabolic
or respiratory acidosis, (2) FiO2 ≥ 60% to keep SpO2 ≥ 92
%, (3) hemodynamic instability (vasopressor requirement
to keep mean arterial pressure (MAP) ≥ 65 mmHg, severe
tachycardia or bradycardia, (4) neurological disorientation.
All failed patients were transferred to the medical ICU
and either NIMV or IMV was applied per ICU team.
2.7. Data collection
We have screened all patients in hematology ward and
bone marrow transplant unit daily, at least ones during
the study period. Hematology team was aware of the study
and we were called by them in case of possible new patient
inclusion at other times of the day.
We have recorded baseline characteristics of the
patients including vital signs, hematological diagnoses,
activity status of the hematological disease, reason for
respiratory insufficiency, APACHE II score, SOFA score,
co-morbid conditions, baseline laboratory values, visual
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analog scale (VAS) for dyspnea, comfort, and sensation
of thirst. VAS scores are collected at the 2nd and 24th
hours after initiation of oxygen or HFNC therapy. Baseline
arterial blood gas and vital signs were recorded. Arterial
blood gas and vital signs were collected at least ones a
day (worst values were recorded). SpO2 was monitored
continuously.
Mortality at 28 days, need for ICU transfer, endotracheal
intubation, NIMV, hospital and ICU length of stay were all
assessed at the end of the study.
2.8. Outcomes
The primary goal of the study to show if HFNC can
decrease need for endotracheal intubation (first 7 days)
for each group. The secondary goals of the study to show
if there is an improvement in mortality (28 days) and
need for invasive and noninvasive ventilation as well as
improvement of VAS score for, dyspnea, and sensation of
thirst (first 7 days) for each group.
2.9. Statistical analysis
All randomized patients were included into the final
analysis. The patients were randomized to either standard
medical treatment or HFNC treatment groups. All
statistical analyses were calculated by using IBM Statistic
SPSS v: 22.0 (Chicago, IL, USA). Data are expressed as
the median (including the lower and upper quartiles).
Comparisons between groups for continuous variables
were performed using the Mann–Whitney U test. The
χ2 test was used to determine significant differences in
proportions among categorical variables. A p value of 0.05
and lower was considered statistically significant.
3. Results
We screened 650 patients and we included 102 patients
into the study. Two patients in HFNC group developed
epistaxis immediately after initiation of HFNC excluded
from the study and 100 patients completed the study. The
median age was 58.5 (18–86) years and 66 patients were
male 34 patients were female. The most common reason
for exclusion was absence of respiratory insufficiency (436
patients). Of the patients who were enrolled, 53 patients
randomly assigned to the HFNC group and 49 patients
to the control group. (Figure). Baseline characteristics of
the patients are shown in Table 1. There was a statistically
significant difference in hemoglobin and APACHE-II
levels between the two groups. All patients had a diagnosis
of hematological malignancy. The most common
hematological malignancies were acute myelomonocytic
leukemia and lymphoma with 43 and 26 patients
respectively. The malignancies were active in 55 patients,
in remission in 12 patients, relapsing disease in 32 patients,
and one patient had graft versus host disease. None of the
patients had do not intubate orders. The most common
reason for respiratory failure was pneumonia and extra
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pulmonary sepsis in 74 and 10 patients, respectively.
At the time of randomization, median APACHE II
score was 18 (5–25) and 16 (7–29) (p = 0.014) and SOFA
score was 6 (2–10) and 5 (0–10) (p = 0.112) in HFNC and
oxygen therapy groups respectively. Charlson comorbidity
index was 0 in 45 patients and 1–2 in 40 patients, 15
patients had an index of 3 and above.
At the time of randomization median PaO2/FiO2
was 257 mmHg (209–295) and 276 mmHg (190–295)
in HFNC group and oxygen therapy group respectively.
All patients in HFNC group received high flow oxygen
immediately after the randomization. The median flow
rate with HFNC was 40 (20–50) L/min and median FiO2
was 0.35 (0.28–0.60). All 51 patients with HFNC were able
tolerate the treatment. Oxygen was given with using face
mask and nasal cannula to the patients in control group
and the median flow rate was 5 (1–15) L/min.
3.1. Primary outcomes
Endotracheal intubation and invasive mechanical
ventilation were required in 17 (33%) patients in HFNC
group and 10 (20%) patients in oxygen group (p = 0.14).
Need for noninvasive mechanical was observed in 17
(33%) and 17 (35%) patients in HFNC group and control
groups respectively (p = 0.88). VAS for comfort, thirst, and
dyspnea were not different between the groups (Table 2).
3.2. Secondary outcomes
There was no significant difference in length of ICU
and hospital stay between the groups. Twenty-eight-day
mortality rate was 45% (23 deaths) and 37% (18 deaths) in
HFNC and control groups respectively (p = 0.395) (Table
2).
4. Discussion
Our RCT showed that HFNC compared to oxygen
therapy delivered via a mask or nasal cannula applied at
hematology and bone marrow transplant wards does not
prevent progression of mild acute respiratory failure to
endotracheal intubation and mechanical ventilation in
hematological malignancy patients.
Acute respiratory failure is an independent factor on
mortality in hematological malignancy patients which
indicates the need for developing better management
strategies [22]. Mechanical ventilation predicts mortality
which may be three times higher in hematological
malignancy patients [23]. Preventive measures that can
decrease need for mechanical ventilation may decrease
mortality in hematological malignancy patients. Early use
of noninvasive ventilation during episodes of pneumonitis
and hypoxemic acute respiratory failure decreased the need
for endotracheal intubation and improved the outcomes in
immunocompromised patients [9].
The patients who received noninvasive ventilation
had significantly lower rates of endotracheal intubation,
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650 Assessed for eligibility

548 Excluded
436 No respiratory failure
37 Hemodynamic instability
36 Decision for non invasive
mechanical ventilation
12 Decision for invasive mechanical
ventilation
27 Unconsciousness

102 Randomized

53 were allocated to receive high flow oxygen
therapy (High flow nasal oxygen group)

2 were excluded due to epistaxis after initiation
of HFNC

51 were analysed for primary outcome

49 were allocated to receive standart oxygen
therapy (Oxygen treatment group)

There was not lost to follow-up in control group
during all study period

49 were analysed in primary outcome

Figure. Patient flow chart. HFNC: high flow nasal oxygen.

complications, mortality compared with patients who
received standard treatment with supplemental oxygen
[9]. However, there are conflicting results from other
randomized studies which showed no benefit from
noninvasive ventilation or even increased intubation rates
[8,10]. Our study also did not find a significantly reduced
intubation rate in hematological malignancy patients.
HFNC can improve oxygenation in hypoxic
respiratory failure and can even decrease mortality
rate [16]. A recent meta-analysis comparing efficacy
of HFNC and conventional oxygen treatment did
not demonstrate a survival benefit compared with
conventional oxygen therapy, HFNC use in patients

with acute hypoxemic respiratory failure may decrease
the need for tracheal intubation [24]. HFNC had no
impact on comfort, dyspnea, or ICU/hospital length of
stay according to this meta-analysis [24]. However, our
study did not find any benefit for intubation rate and
comfort of HFNC in immunocompromised patients
with respiratory failure although our patients had mild
respiratory failure compared to the other studies and
our patients were at wards not in intensive care units
[16,20,25]. The intubation rate found to be lower in
patients with severe hypoxemia (PaO2/FiO2 < 200) in a
post hoc analysis and our group has median PaO2/FiO2
ratio above 250 which may explain the ineffectiveness
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Table 1. Patients demographic, clinical and laboratory characteristics.
Total
n=100

Intervention group
(High flow) n=51

Control group
(Standard O2) n=49

P

58.5 (18-86)

58 (18-86)

59 (27-81)

0.586*

Male

66(66)

33(65)

33(67)

Female

34(34)

18(35)

16(33)

AML

43(43)

24(47)

19(39)

Lymphoma

26(26)

13(25)

13(26)

Multiple Myeloma

19(19)

6(12)

13(26)

MDS

6(6)

5(10)

1(2)

ALL

4(4)

1(2)

3(7)

KLL

1(1)

1(2)

0(0)

KML

1(1)

1(2)

0(0)

Pneumonia

74(74)

40(78)

34(70)

Extra pulmonary Sepsis

10(10)

6(12)

4(8)

Pleural effusion

7(7)

3(6)

4(8)

Non-infections pulmonary disease

4(4)

0(0)

4(8)

CHF

2(2)

1(2)

1(2)

ARDS

1(1)

0(0)

1(2)

Other

2(2)

1(2)

1(2)

APACHE II score,median (min-max)

17 (5-29)

18 (5-25)

16 (7-29)

0.014*

SOFA score, median (min-max)

6 (0-10)

6 (2-10)

5 (0-10

0.112*

GCS, median (min-max)

15 (12-15)

15 (13-15)

15(12-15)

0.715*

CCI, median (min-max)

3 (1-10)

3 (2-9)

3 (1-10)

0.282*

PaO2/FiO2 ratio, median (min-max)

262 (190-295)

257 (209-295)

276 (190-295)

0.073*

pH, median (min-max)

7.48 (7.31-7.59)

7.48 (7.31-7.59)

7.49 (7.36-7.59)

0.178*

PO2, median (min-max)

55.1 (40-62)

53.4 (44-62)

58 (40-62)

0.062*

PCO2, median (min-max)

30 (17-41)

30 (17-41)

32.5 (19-41)

0.444*

HCO3, median (min-max)

23 (11.6-31.6)

23.3 (13.9-30.6)

23 (11.6-31.6)

0.646*

Lactate, mmol/L median (min-max)

1.43 (0.57-8.40)

1.50(0.6-4.8)

1.40(0.57-8.4)

0.497*

Hemoglobin concentration, median (min-max) 8.45 (4.5-13.6)

8.2 (4.5-11.3)

8.7 (6.3-13.6)

0.030*

White blood cell count/μL, median (min-max)

4985 (0.0-169300)

5580 (0.0-169300)

4060 (0.0-93390)

0.409*

Platelet count/μL median (min-max)

34000 (4000-385000)

33000(6000-290000)

35000 (4000-385000) 0.581*

Age, years (min-max)
Gender, n (%)

0.780**

Hematologic disease, n (%)

0.186**

Reason for acute respiratory failure, n (%)
0.424**

AML: acute myelomonocytic leukemia, MDS: myelodysplastic syndrome, ALL: acute lymphocytic leukemia, CLL: Chronic lymphocytic
leukemia, CML: chronic myelomonocytic leukemia, CCI: Charlson comorbidity index.
*Comparisons between groups were performed using the Mann–Whitney U test. **Comparisons between groups were performed using
the chi-square test.

of HFNC in our study [16]. Most studies on HFNC in
patients with hypoxemia have been conducted in an ICU
or high-dependency unit. Authors in a narrative about
the mechanism of action and clinical implications of
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HFNC recommend that HFNC use be limited to ICUs
or intermediate care units and its use on regular wards
should be discouraged [21]. However, HFNC has been
studied in emergency services, postoperative patients
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Table 2. Patient’s clinical outcomes.
Variables

High Flow Nasal Oxygen
Treatment n=51

Standard Oxygen Theraphy
n=49

P*

Need for intubation, n (%)

17 (33)

10 (20)

0.146

Need for non-invasive MV, n (%)

17 (35)

17 (33)

0.886

2 hours

6 (1-9)

6 (0-9)

0.481

24 hours

4 (0-7)

4 (0-9)

0.984

2 hours

6 (2-9)

6 (0-9)

0.182

24 hours

4 (0-10)

4 (0-9)

0.857

2 hours

4 (0-10)

5 (0-9)

0.957

24 hours

3.5 (0-8)

4 (0-9)

0.307

Need for ICU admission, n (%)

18(35)

11(22)

0.157

Length of ICU stay, day (min-max)

3 (1-36)

3.5 (1-18)

0.470

Length of hospital stay, day (min-max)

28 (3-126)

30 (3-130)

0.542

28-day mortality, n (%)

23 (45)

18 (37)

0.395

VAS, Dispne (min-max)

VAS, Comfort (min-max)

VAS, Thirst (min-max)

VAS: Visual analog scale, * Need for intubation and need for noninvasive MV parameters were performed using chisquare test. Other parameters were performed using Mann–Whitney U test.

and in palliative care units [26–28]. There is limited
information HFNC applied at wards in pediatric and
adult population [29–31]. HFNC outside the ICU was
associated with improved visual analog scale score,
breathing frequency, and saturation but with a relatively
high mortality, care should be exercised in using this
therapy in a setting that is not continuously monitored
[31]. Our hematology and bone marrow transplantation
units have continuous pulse oximetry and ECG
monitoring on demand of the caring team. The patients
were transferred to the ICU as they required per caring
team. Patients required HFNC at wards should have low
threshold for ICU transfer or HFNC treatment should
be applied in the ICU.
Our 28-day mortality rate was similar with other
studies [20] although our patients have less severe
respiratory failure. It was shown that delay in ICU
management is associated with mortality [32]. Our
patients were followed at hematology ward which may
cause delay to ICU admission although we had certain
criteria for treatment failure in our patients. Invasive and
noninvasive mechanical ventilation more often required in
hematological malignancy patients with respiratory failure
[33]. We observed significant number of our patients
progressed from mild respiratory failure to more severe
form and required invasive and noninvasive mechanical
ventilation.

Dryness and discomfort were found to be significantly
lower in the HFNC patients compared standard
nonhumidified oxygen therapy in a randomized trial
in patients with ARF who did not require immediate
NIV or MIV [13]. However, these patients were not
immunocompromised and less severe patients. Comfort,
thirst and dyspnea VAS scores were not different with
HFNC and standard oxygen treatment groups in a group
of immunocompromised hypoxemic respiratory failure
patients as similarly with our study [34].
Our study has several limitations. Firstly, limited
number of the patients and we did not perform power
analysis prior to the study. Secondly, therapies were not
blinded. Thirdly, since we performed the study in a ward,
the results are not applicable to the patients in intensive
care units. Finally, limited statistical power because of the
modest sample size in the present study (n = 100) may
have played a role in limiting the significance of some of
the statistical comparisons conducted. A post hoc power
analysis revealed that on the basis of the mean, betweengroups comparison effect size observed in the present study
(d = 0.29), an n of approximately 358 would be needed to
obtain statistical power at the recommended 0.80 level [35].
5. Conclusion
In hematological malignancy patients with mild acute
respiratory failure HFNC compared to oxygen treatment
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delivered via a mask or nasal cannula did not improve the
need for ICU transfer, requirement for either noninvasive
mechanical ventilation or invasive mechanical ventilation.
There were also no significant differences in VAS scores
for dyspnea, comfort, and thirst between both treatment
groups. The requirement of invasive and noninvasive
mechanical ventilation, length of hospital stay, ICU
stay, and 28-day mortality between HFNC and oxygen
delivered via a mask were similar. Standard medical
treatment and oxygen support with mask or nasal cannula

must be main approach to mild respiratory failure patients
with hematological malignancy who are treated at wards.
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